Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478725 · ClinicalTrials.gov registry record · Phase 1
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00478725: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT00478725 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478725, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
Interventions
- DRUG GW786034, oral
- DRUG GW786034, IV
- DRUG GW786034, radiolabeled oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-07-18 |
| Est. Completion | 2008-07-01 |
| Phase | Phase 1 |
What the finished NCT00478725 record still lists
NCT00478725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which GW786034, oral is the first listed.
NCT00478725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00478725 about?
NCT00478725 is a clinical study titled "Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034". To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
What is the current status of trial NCT00478725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-07-18. Estimated completion is 2008-07-01.
What interventions are being tested in trial NCT00478725?
The interventions under investigation include: GW786034, oral (DRUG), GW786034, IV (DRUG), GW786034, radiolabeled oral (DRUG).
Who is sponsoring clinical trial NCT00478725?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00478725's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI